Mitsuyuki Matsumoto, Ph.D.

Scientific Founder & Chief Scientific Officer

Professional Overview
Dr. Mitsuyuki Matsumoto is a highly accomplished biopharmaceutical research executive with over 30 years of industry experience. As the Scientific Founder and Chief Scientific Officer of Arialys Therapeutics, Inc., he leverages his deep expertise in neuroscience and psychiatric drug discovery to lead the company's innovative research programs. Additionally, he serves as an Adjunct Research Professor of Psychiatry and the Behavioral Sciences at the University of Southern California, further contributing to the advancement of psychiatric care through his academic work.

Experience Summary

Current Role
As the Scientific Founder and Chief Scientific Officer of Arialys Therapeutics, Dr. Matsumoto is responsible for overseeing the company's entire research and development pipeline. He is spearheading the development of novel therapeutics for the treatment of psychiatric disorders, with a focus on precision psychiatry. Under his leadership, Arialys has established a strong portfolio of early-stage drug candidates and forged strategic partnerships to accelerate their clinical progress.

Career Progression
Prior to his current role, Dr. Matsumoto held several senior positions at Astellas Pharma, where he made significant contributions to the company's neuroscience and psychiatric drug discovery efforts. He served as the Precision Psychiatry TaskForce Leader, the Virtual Venture Unit Head for Psychiatry, and the Executive Director leading the Neuroscience Research Unit and Candidate Discovery Science Labs. Earlier in his career, he was a Research Scientist and Group Leader at Yamanouchi Pharmaceutical Co. and a Visiting Scientist at the National Institute of Mental Health, NIH.

Academic Background
Dr. Matsumoto holds a Ph.D. in Neuroscience from Northwestern University, where he also held an Adjunct Professor position from 2010 to 2017. His academic research has focused on the neurobiology of psychiatric disorders, and he has published extensively in peer-reviewed journals.

Areas of Expertise

• Neuroscience and psychiatric drug discovery

• Precision psychiatry and personalized medicine

• Translational research and early-stage drug development

• Strategic leadership and team management

• Academic-industry collaboration and knowledge transfer

Professional Impact
Throughout his career, Dr. Matsumoto has made significant contributions to the field of psychiatric drug discovery. His work has led to the identification of several promising drug candidates, some of which have advanced into clinical trials. He has also been instrumental in fostering collaborations between academic institutions and the biopharmaceutical industry, driving the translation of cutting-edge research into practical clinical applications.

Conclusion
With his deep scientific expertise, proven track record of success, and visionary leadership, Dr. Mitsuyuki Matsumoto is poised to make a lasting impact on the future of psychiatric care. As the Scientific Founder and Chief Scientific Officer of Arialys Therapeutics, he is dedicated to developing innovative therapies that address the unmet needs of patients suffering from mental health conditions.